Jay Mattheis, MD
Ophthalmology · Loma Linda, CANPI 1154311058
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $109,809 of the $176,323 with a category attached, or 62.3%. 20 manufacturers reported payments, led by Novartis at 25.3% of the total. Reporting peaked in 2019 at $120,725 and has fallen 99.5% since, to $621 in 2025. Among ophthalmology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 406 payments — averaging $434.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$45K
- Shire North American Group Inc$42K
- Sun Pharmaceutical Industries Inc.$25K
- Biotissue Holdings Inc.$23K
- Aerie Pharmaceuticals, Inc.$20K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$10K
- plus $11K from 14 others
What the payments were for
- Consulting fees$28,80516%
- Speaking & faculty fees$109,80962%
- Travel & lodging$26,87215%
- Food & beverage$10,8376%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 63 | $44,660 |
| Shire North American Group Inc | 83 | $41,587 |
| Sun Pharmaceutical Industries Inc. | 39 | $24,870 |
| Biotissue Holdings Inc. | 32 | $23,283 |
| Aerie Pharmaceuticals, Inc. | 56 | $20,258 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 48 | $10,195 |
| Kala Pharmaceuticals, Inc. | 17 | $9,476 |
| Bausch & Lomb Americas Inc. | 17 | $579 |
| Alcon | 11 | $343 |
| AbbVie(2 entities) | 19 | $307 |
| Sight Sciences, Inc. | 3 | $193 |
| Eyevance Pharmaceuticals LLC | 2 | $151 |
| ANI Pharmaceuticals, Inc. | 4 | $122 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $76 |
| Apellis Pharmaceuticals, Inc. | 2 | $54 |
| Regeneron Healthcare Solutions, Inc. | 2 | $52 |
| Akorn Operating Company LLC | 2 | $42 |
| Dompe US, Inc. | 1 | $30 |
| Staar Surgical Company | 2 | $25 |
| Glaukos Corporation | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XIIDRA$84,219
- CEQUA$24,209
- Prokera$22,471
- AmnioGraft$22,471
- AmnioGuard$22,471
- Rocklatan$19,577
- Rhopressa$14,876
- EYSUVIS$9,186
- LOTEMAX SM$5,263
- VYZULTA$4,507
- MIEBO$255
- Zerviate$148
- TRYPTYR$147
- XIPERE$130
How this compares
$176,323 in reported general payments places this provider in the 95th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 260 | $285,265 |
| LumiganBimatoprost | 75 | $39,299 |
| RocklatanNetarsudil Mesylat/Latanoprost | 35 | $25,689 |
| Restasis MultidoseCyclosporine | 32 | $25,225 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 68 | $24,695 |
| RestasisCyclosporine | 26 | $20,996 |
| Brimonidine Tartrate | 419 | $18,811 |
| Cyclosporine | 36 | $16,824 |
| VyzultaLatanoprostene Bunod | 30 | $13,821 |
| RhopressaNetarsudil Mesylate | 21 | $13,051 |
| Alphagan PBrimonidine Tartrate | 29 | $11,928 |
| Latanoprost | 1,126 | $10,135 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 471 | $6,899 |
| EysuvisLoteprednol Etabonate | 13 | $6,238 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 39 | $6,130 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $579 | $299,086290 claims |
| AbbVieLumigan, Restasis Multidose, Restasis, Alphagan P | $307 | $97,448162 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $20,258 | $38,74156 claims |
| AlconSimbrinza | $343 | $24,69568 claims |
| Kala Pharmaceuticals, Inc.Eysuvis | $9,476 | $6,23813 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $10,195 | $4,18736 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Loma Linda
- John AffeldtLoma Linda$1.1M
- Daniel SchwartzSan Francisco$8M
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- Raymond DouglasBeverly Hills$1.3M
- Srinivas SaddaPasadena$1M
- Sheri RowenNewport Beach$1M
- Savak TeymoorianLaguna Hills$955K
- Andrew MoshfeghiLos Angeles$895K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.